Suitability of Metastatic Lung Tumors for Stereotactic Body Radiotherapy

Abstract

We investigated factors influencing local control of lung metastases treated with stereotactic body radiotherapy (SBRT) and determined the type of lesions for which SBRT is more suitable. Ninety-six patients and 196 tumors were included. Median follow-up duration was 32.0 months (range 4.7–95.8). The two-year local recurrence rate was 15.2% (95% confidence interval: 10.2–21.3). Multivariate analysis revealed biological effective dose, ultracentral tumor location, reirradiation, and prior chemotherapy as significant factors. SBRT is suitable for lung metastases, especially for peripheral tumors and those located in the inner lung parenchyma. For ultracentral lesions and recurrent lesions after SBRT, metastasectomy is recommended.

Keywords:

• Stereotactic body radiotherapy
• SBRT
• metastasectomy
• metastatic lung tumor
• lung metastasis

Acknowledgments

The authors thank Editage (www.editage.jp) for English language editing.

Declaration of interest

No potential conflict of interest was reported by the authors.

Data availability statement

The data that support the findings of this study are available from the corresponding author, [T.E.], upon reasonable request.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.